EP4304563A1 - Pullulan capsules - Google Patents
Pullulan capsulesInfo
- Publication number
- EP4304563A1 EP4304563A1 EP22700765.5A EP22700765A EP4304563A1 EP 4304563 A1 EP4304563 A1 EP 4304563A1 EP 22700765 A EP22700765 A EP 22700765A EP 4304563 A1 EP4304563 A1 EP 4304563A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- capsshell
- acyl gellan
- pullulan
- gellan
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Definitions
- the invention discloses a hard capsule shell comprising pullulan, low acyl gellan, high acyl gellan and KC1.
- Hard capsules are used as dosage forms for pharmaceuticals or nutraceuticals.
- US 3,258,115 discloses a two-piece hard gelatin capsule, the gelatin forms the shell of the capsule.
- Gelatin is commonly derived from collagen taken from animal body parts which is not acceptable for vegetarians.
- HAG High acyl gellan CAS 71010-52-1, also called native gellan with two acyl substituents acetate and gly cerate
- HPMC hydroxypropyl methylcellulose also called hypromellose or Cellulose, 2- hydroxypropyl methyl ether or cellulose hydroxypropyl methyl ether, CAS 9004- 65-3
- HPMCAS hydroxypropyl methylcellulose acetate succinate
- HPMCP hypromellose acetate succinate
- LAG Low acyl gellan CAS 71010-52-1, prepared from High acyl gellan by removing the acyl groups.
- Subject of the invention is a hard capsule shell, CAPSSHELL, comprising 95 to 98.7 wt% of pullulan;
- CAPSSHELL is a two piece hard capsule shell.
- the two pieces are the cap and the body of the capsule shell which are telescopically joined with each other when closing CAPSSHELL.
- CAPSSHELL does not comprise gelatin, HPMC, PVA or modified starch.
- CAPSSHELL does not comprise a polymer selected from the group of HPMCAS, HPMCP, CAP, and polyacrylic acid copolymers.
- CAPSSHELL does not comprise any other film forming polymer besides pullulan.
- KC1 when used in combination with a gelling agent, is known to the skilled person as being a gelling aid. So the combination of low acyl gellan, high acyl gellan and KC1 in CAPSSHELL is a combination of a gelling agent and a gelling aid.
- CAPSSHELL does not contain a gelling agent other than the combination of low acyl gellan and high acyl gellan; and CAPSSHELL does not contain a combination of a gelling agent with a gelling aid other than the combination of low acyl gellan, high acyl gellan and KC1.
- CAPSSHELL comprises 95 to 98.4 wt% of pullulan
- CAPSSHELL comprises 95 to 98.3 wt% of pullulan
- CAPSSHELL further comprises sucrose monolaurate.
- CAPSSHELL comprises sucrose monolaurate
- CAPSSHELL comprises from 0.05 to 0.25 wt%, more preferably from 0.1 to 0.2 wt%, of sucrose monolaurate, with the wt% being based on the dry capsule weight.
- CAPSSHELL further comprises sorbitan mono laurate.
- CAPSSHELL comprises sorbitan mono laurate
- CAPSSHELL comprises from 0.01 to 0.05 wt%, more preferably from 0.02 to 0.04 wt%, of sorbitan mono laurate, with the wt% being based on the dry capsule weight.
- CAPSSHELL further comprises NaHCCh.
- CAPSSHELL comprises NaHCCh
- CAPSSHELL comprises from 0.02 to 0.06 wt%, more preferably from 0.03 to 0.05 wt%, of NaHCCh, with the wt% being based on the dry capsule weight.
- CAPSSHELL may comprise water.
- the water may stem from the production process which may be using an aqueous composition for preparing CAPSSHELL, so the water in CAPSSHELL is typically residual water remaining in CAPSSHELL after drying.
- the water may also stem from the humidity of the atmosphere, essentially of the relative humidity of the air, surrounding CAPSSHELL.
- Typical upper limit of the amount of residual water in CAPSSHELL is 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, the wt% being based on the weight of the CAPSSHELL.
- Typical lower limit of the amount of residual water in CAPSSHELL is 1 wt% or more, preferably 2 wt% or more, more preferably 3 wt% or more, the wt% being based on the weight of the CAPSSHELL.
- the amount of residual water in CAPSSHELL may be from 1 to 20 wt%, preferably from 2 to 15 wt%, more preferably from 3 to 10 wt%, the wt% being based on the weight of the CAPSSHELL.
- the amount of residual water may be characterized by the loss on drying, LOD.
- the dry capsule weight is the capsule weight minus the weight that is lost when the LOD is determined, that is the remaining capsule weight after the LOD determination.
- CAPSSHELL consists of pullulan, low acyl gellan, high acyl gellan,
- CAPSSHELL contains at least 95 wt% of pullulan, with the wt% being based on the weight of the CAPSSHELL.
- CAPSSHEL is prepared by dip molding; with CAPSSHELL as defined herein, also with all its embodiments.
- melt In dip molding an aqueous mixture of the components of CAPSSHELL, this aqueous mixture is called melt.
- a mold pin is dipped into the melt and then extracted from the melt.
- the melt on the outer surface of the mold pin solidifies to form a film, which is still a wet gel.
- the film is dried at 20 to 80 °C. After drying, unnecessary portions thereof are cut off to produce a body and a cap respectively, for producing a body a respectively shaped mold pin is used for the dip molding, and for producing the cap a respectively shaped mold pin is used for the dip molding.
- a pair of the body and the cap constitutes CAPSSHELL; by telescopically engaging the cap with the body a closed CAPSSHELL is obtained.
- CAPSSHELL filled with an active agent, AA with AA being selected from the group drug, medicament, pharmaceutical, therapeutic agent, nutraceutical, and active pharmaceutical ingredient, API; with CAPSSHELL as defined herein, also with all its embodiments.
- HAG High acyl gellan CAS 71010-52-1, KELCOGEL® CG -HA Gellan Gum, from
- Tube tester developed in-house by Capsugel, now Lonza Ltd, Visp, Switzerland:
- the capsule’s fracture and elasticity behavior is measured by its resistance to an impact test with a tube.
- Step 1 Preparation of gellan melt in Step 1 was done by filling a vessel with ion exchanged water of 80 to 85 °C into which NaHC03 was charged and mixed for 5 min. A blend of gellans (LAG and HAG) was then added and mixed for 200 min. A solution of 10 % KC1, prepared according to Step 2, was added into the vessel which was then cooled to 68 °C.
- Step 4 in Table 1 gives a summary.
- the mixture was kept stirring at 68 °C for 60 min for debubbling until no bubbles were observed anymore and then for further 90 min for ageing, providing the pullulan melt.
- the pullulan melt was transferred to a transfer tank at 65 °C. 1.4 kg of SE solution, prepared according to step 3a, and 0.3 kg of SML solution, prepared according to step 3b, were mixed to provide a surfactant solution The surfactants solution was added to the pullulan melt in the transfer tank; with gentle mixing and maintaining 65 °C, providing the Plantcaps Gellan Melt for further use for dip molding.
- Table 1 gives the amounts of the components that were used.
- Table 2 gives the composition of the Plantcaps Gellan Melt and of the final capsule based on dry weight of capsule.
- Plantcaps Gellan Melt prepared according to example 1, was used to produce shells in form of capsule halves (bodies and caps) with capsule size 2 and standard target weights (capsule weight 61 +1- 4 mg) through conventional dip molding by dipping stainless steel mold pins with a temperature of 22 °C into the Plantcaps Gellan Melt with a temperature of 60 °C.
- a film was formed on the mold pins. After first drying of the film on the mold pins at 26 °C and 44 % RH for 15 to 20 min, a second drying at 32 °C and 25 to 30 % RH for 30 min was applied and finally a drying at 22 °C and 50 % RH was applied before stripping the capsule parts from the metal pins. The capsule halves were removed from the mold pins.
- Capsules were assembled by joining always one cap with one body.
- the fracture behavior of the capsules was measured by their resistance to an impact test with a tube tester.
- the capsules were stored for equilibration for five days under four storage conditions in desiccators: 10, 23, 33 and 45 % RH in order to obtain capsules with different LOD.
- the number of capsules tested was 50 per each RH value and the number of broken bodies or broken caps was recorded. Percentage of broken capsules is presented in Table 3.
- Example 4 Testing of capsules - Disintegration of Capsules
- Capsules prepared according to Example 2, were tested for disintegration in a disintegration tester, Sotax DT2, SOTAX AG, 4147 Aesch, Switzerland, in accordance to the USP specifications.
- the capsules were filled with 320 +/- 10 mg of a blend of Lactose containing 0.1 wt% of Indigocarmin dye.
- the capsules were placed in the different media at 37 °C +/- 1 °C and the time of first leak, of capsule emptying and of total disintegration of the capsule were recorded.
- Example 5 Testing on capsules - Dissolution of capsules
- the capsules, prepared according to Example 2 were tested for dissolution performance in different media: pH 1.2 USP, DM water USP and pH 6.8 USP using a Sotax AT70smart, SOTAX AG, 4147 Aesch, Switzerland, dissolution bath at 37 °C with paddle at 50 rpm, acetaminophen dissolution was followed with Perkin Elmer Lambda 25 UV / VIS spectrometer at 300 nm wavelength. Capsules were filled with Acetaminophen (APAP, Sigma Aldrich Ref A5000).
- Table 5 shows the results as measured % of dissolution of the APAP contained in the capsules over time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21162354 | 2021-03-12 | ||
| PCT/EP2022/050500 WO2022189045A1 (en) | 2021-03-12 | 2022-01-12 | Pullulan capsules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP4304563A1 true EP4304563A1 (en) | 2024-01-17 |
| EP4304563B1 EP4304563B1 (en) | 2024-12-04 |
| EP4304563C0 EP4304563C0 (en) | 2024-12-04 |
Family
ID=74873617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22700765.5A Active EP4304563B1 (en) | 2021-03-12 | 2022-01-12 | Pullulan capsules |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240165038A1 (en) |
| EP (1) | EP4304563B1 (en) |
| JP (1) | JP2024510587A (en) |
| CN (1) | CN116997329A (en) |
| CA (1) | CA3211764A1 (en) |
| ES (1) | ES3002507T3 (en) |
| PL (1) | PL4304563T3 (en) |
| WO (1) | WO2022189045A1 (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3258115A (en) | 1965-05-12 | 1966-06-28 | Scherer Corp R P | Two-piece hard gelatin capsule |
| EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| US20070034827A1 (en) * | 2005-12-02 | 2007-02-15 | Zhixin Li | Blends of gelling and non-gelling starches with gellan gums and plasticizer |
| ES2605962T3 (en) * | 2007-02-15 | 2017-03-17 | Qualicaps Co., Ltd. | Band sealing element for a hard capsule filled with PEG |
| CN101433526B (en) * | 2007-11-13 | 2012-04-18 | 上海慧源植物胶囊股份有限公司 | Non-gelatin enteric hard capsule shell material and production method thereof |
| ES2556985T3 (en) * | 2011-01-11 | 2016-01-21 | Capsugel Belgium Nv | New hard capsules comprising pululane |
| WO2016195498A1 (en) * | 2015-06-05 | 2016-12-08 | Frieslandcampina Nederland B.V. | Self-supporting dairy composition |
| US10350568B2 (en) * | 2016-05-19 | 2019-07-16 | Jiangsu Lefan Capsule Co., Ltd. | Membrane-forming composition, soft and hard capsules prepared based on this composition and the preparation methods |
| CN106109437B (en) * | 2016-07-13 | 2020-02-18 | 江苏力凡胶囊有限公司 | Film forming composition, soft and hard capsules prepared based on film forming composition and preparation method of soft and hard capsules |
| CN106236730B (en) * | 2016-08-25 | 2019-03-29 | 江苏力凡胶囊有限公司 | A kind of pulullan polysaccharide empty capsule and preparation method thereof |
| JP6887456B2 (en) * | 2018-07-04 | 2021-06-16 | キャプシュゲル・ベルジウム・エヌ・ヴィ | A film-forming composition containing a surfactant or a surfactant and a salt as a whitening agent. |
-
2022
- 2022-01-12 JP JP2023555497A patent/JP2024510587A/en active Pending
- 2022-01-12 ES ES22700765T patent/ES3002507T3/en active Active
- 2022-01-12 CN CN202280019869.3A patent/CN116997329A/en active Pending
- 2022-01-12 US US18/549,330 patent/US20240165038A1/en active Pending
- 2022-01-12 PL PL22700765.5T patent/PL4304563T3/en unknown
- 2022-01-12 CA CA3211764A patent/CA3211764A1/en active Pending
- 2022-01-12 EP EP22700765.5A patent/EP4304563B1/en active Active
- 2022-01-12 WO PCT/EP2022/050500 patent/WO2022189045A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3211764A1 (en) | 2022-09-15 |
| EP4304563B1 (en) | 2024-12-04 |
| JP2024510587A (en) | 2024-03-08 |
| PL4304563T3 (en) | 2025-03-31 |
| CN116997329A (en) | 2023-11-03 |
| US20240165038A1 (en) | 2024-05-23 |
| ES3002507T3 (en) | 2025-03-07 |
| EP4304563C0 (en) | 2024-12-04 |
| WO2022189045A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101762460B1 (en) | Acid resistant capsules | |
| JP5248739B2 (en) | Enteric preparation | |
| JP3822810B2 (en) | Capsule sealing method | |
| US5756123A (en) | Capsule shell | |
| CA2585721A1 (en) | Non-gelatin soft capsule system | |
| WO2004014344A1 (en) | Film coating for tablets and caplets | |
| CN105873455A (en) | Enteric coating composition, enteric coating film and food preparation | |
| EP4304563B1 (en) | Pullulan capsules | |
| KR102928516B1 (en) | Capsule shell comprising core-shell polymer and cellulose | |
| HK40095658A (en) | Pullulan capsules | |
| US20230414524A1 (en) | Double layered delayed-release hard capsules | |
| HK40089635A (en) | Double layered delayed-release hard capsules | |
| CN116456973A (en) | Double-layer delayed release hard capsule | |
| MXPA00002854A (en) | Gelatine compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230807 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240826 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602022008407 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20241211 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20241220 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 4 Effective date: 20250127 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3002507 Country of ref document: ES Kind code of ref document: T3 Effective date: 20250307 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250304 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250305 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250304 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250404 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: L10 Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20251015 |
|
| 26N | No opposition filed |
Effective date: 20250905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250112 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20251229 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260201 |
|
| U1N | Appointed representative for the unitary patent procedure changed after the registration of the unitary effect |
Representative=s name: DE CLERCQ & PARTNERS; BE |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 5 Effective date: 20260126 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20260126 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20260210 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20260201 Year of fee payment: 5 |